Diagnosis and treatment of hepatic encephalopathy

Best Practice and Research: Clinical Gastroenterology

Volumn 14, Issue 6, 2000, Pages 959-974

  Blei, Andres T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute liver failure; Ammonia; Benzodiazepines; Hepatic encephalopathy; Non absorbable disaccharides

Indexed keywords

AMINO ACID; AMMONIA; ANTIBIOTIC AGENT; ASPARTIC ACID; BENZODIAZEPINE; BENZOIC ACID; BROMOCRIPTINE; CYTOKINE; DISACCHARIDE; ENEMA; FLUMAZENIL; GLUCOSE; LACTITOL; LACTULOSE; MANNITOL; METRONIDAZOLE; NEOMYCIN; NITROGEN; ORNITHINE; PLACEBO; PROTEIN; SORBITOL; SUCROSE; TOXIN; ZINC;

ARTICLE; ASTROCYTE; BRAIN FUNCTION; CELL SWELLING; CHILD; COLON; COLON LAVAGE; DIAGNOSTIC IMAGING; DIET RESTRICTION; DRUG TARGETING; ELECTROENCEPHALOGRAM; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE; LIVER CELL DAMAGE; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; NEUROTRANSMISSION; OTOTOXICITY; PORTOSYSTEMIC ANASTOMOSIS;

EID: 0034508481     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2000.0141     Document Type: Article

References (81)

1. Fulminant and subfulminant liver failure: Definitions and causes
2. Acute liver failure: Redefining the syndromes
3. Brain edema and portal-systemic encephalopathy
4. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure
5. Clinical and radiologic features of cerebral edema in fulminant hepatic failure
6. Elevation of intracranial pressure following transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage
7. Cerebral oedema and increased intracranial pressure in chronic liver disease
8. Prognostic significance of hepatic encephalopathy in patients with cirrhosis
9. Portal hemodynamics in chronic portal-systemic encephalopathy. Angiographic study in seven cases
10. Subclinical hepatic encephalopathy impairs daily functioning
11. High prevalence of sleep disturbance in cirrhosis
12. Increased blood manganese in cirrhotic patients: Relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms
13. Intrahepatic portal-hepatic venous anastomosis: A portal-systemic shunt with neurological repercussions
14. Hepatic encephalopathy: An update of pathophysiologic mechanisms
15. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration
16. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy
17. Chronic hyponatremia exacerbates ammonia-induced brain edema in rats after portacaval anastomosis
18. Endogenous ligands for benzodiazepine recognition sites
19. Endozepine stupor. Recurring stupor linked to endozepine-4 accumulation
20. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An Italian multicenter double-blind, placebo-controlled, cross-over study
21. Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?
22. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: Relation to severity of liver disturbance
23. Pathways and mechanisms for cytokine signaling of the central nervous system
24. Electron microscopic evaluation of brain edema in rabbits with galactosamine-induced fulminant hepatic failure: Ultrastructure and integrity of the blood-brain barrier
25. Electron microscopic study of brain capillaries in cerebral edema from fulminant hepatic failure
26. Hepatic encephalopathy in chronic liver disease: A clinical manifestation of astrocyte swelling and low-grade cerebral edema
27. Astrocytic-ammonia interactions in hepatic encephalopathy
28. Objective measurement of hepatic encephalopathy by means of automated EEG analysis
29. The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis
30. Partial pressure of ammonia versus ammonia in hepatic encephalopathy
31. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial
32. Medical management of brain edema in fulminant hepatic failure
33. Role of nutrition in hepatic encephalopathy
34. Dietary management of hepatic encephalopathy in cirrhotic patients: Survey of current practice in the United Kingdom
35. ESPEN guidelines for nutrition in liver disease and transplantation
36. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison
37. Ammonia production in the human colon. Effects of cleansing, neomycin and acetohydroxamic acid
38. [Is the intestinal lavage with a solution of mannitol effective in the prevention of post-hemorrhagic hepatic encephalopathy in patients with liver cirrhosis? Results of a randomized prospective study]
39. Treatment of hepatic encephalopathy
40. Complications of cirrhosis III. Hepatic encephalopathy
41. A controlled clinical trial of lactulose in hepatic encephalopathy
42. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial
43. [Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt]
44. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis
45. Hypernatremia in hepatic failure
46. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: A double-blind, randomized clinical trial
47. Neomycin reduces the intestinal production of ammonia from glutamine
48. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy
49. [Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial]
50. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial
51. Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy A double-blind randomized controlled study
52. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: A randomized clinical study
53. Metronidazole pharmacokinetics in patients with hepatic encephalopathy
54. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis
55. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial
56. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial
57. Management of hepatic encephalopathy with oral zinc supplementation: A long-term treatment
58. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis
59. l-ornithine-l-aspartate in experimental portal-systemic encephalopathy: Therapeutic efficacy and mechanism of action
60. Therapeutic efficacy of l-ornithine-l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study
61. Oral l-ornithine-l-aspartate therapy of chronic hepatic encephalopathy: Results of a placebo-controlled double-blind study
62. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis
63. Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial
64. Flumazenil in cirrhotic patients in hepatic coma: A randomized double-blind placebo-controlled crossover trial
65. Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study
66. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: Double-blind pragmatic randomized, placebo study
67. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: A double blind, randomised, placebo controlled multicentre study
68. Flumazenil vs placebo for hepatic encephalopathy in patients with cirrhosis
69. Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy
70. The effect of flumazenil on subclinical psychometric or neurophysiological alterations in cirrhotic patients: A double-blind placebo-controlled study
71. Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: A unified theory of portal-systemic encephalopathy
72. Branched chain amino acids in the management of chronic liver disease. Facts and fantasies
73. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy
74. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis
75. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy: Meta analysis
76. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study
77. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy
78. Treatment of chronic portal systemic encephalopathy with bromocriptine: A double-blind controlled trial
79. Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy
80. Subclinical hepatic encephalopathy
81. Neuropsychological characterization and detection of subclinical hepatic encephalopathy